Jump to navigation Jump to search
CXL-1427 is an experimental drug for the treatment of acute decompensated heart failure. It was created by Cardioxyl Pharmaceuticals, which was acquired by Bristol-Myers Squibb. It is a nitric oxide donor.
- Alternative Names: BMS-986231; CXL 1427; HNO Donor. "BMS 986231 - AdisInsight". Adisinsight.springer.com. Retrieved 2017-05-22.
- Alternative Names: CXL-1020. "CXL 1020 - AdisInsight". Adisinsight.springer.com. Retrieved 2017-05-22.
- "A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure - Full Text View". ClinicalTrials.gov. Retrieved 2017-05-22.
|This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.|